Health
Eli Lilly’s Oral Pill Shows Strong Weight Loss Results in Clinical Trials
Eli Lilly’s new oral pill, orforglipron, has demonstrated up to 8% weight loss in clinical trials, outperforming existing oral semaglutide alternatives. The results signal growing competition in the weight-loss drug market, where demand for convenient and effective treatments continues to rise.
The trial, published in The Lancet, involved more than 1,600 participants with type 2 diabetes across over 130 research centres in five countries. Participants were assigned to different doses of orforglipron, ranging from 12mg to 36mg, or equivalent doses of oral semaglutide for one year.
Results showed that roughly 60% of those taking orforglipron lost at least 5% of their body weight, compared with 40% of participants on semaglutide. Between 28% and 44% of patients on orforglipron lost 10% or more, while only 13% to 21% of those on semaglutide reached similar reductions. Participants also experienced improved blood sugar control, with orforglipron lowering glucose levels more effectively than its competitor.
Experts welcomed the results but urged caution. Naveed Sattar, professor of cardiometabolic medicine at the University of Glasgow, said oral medications that help patients lose weight and maintain it are vital, noting that excess weight is a key driver of type 2 diabetes and associated cardiovascular risks. Marie Spreckley, a weight management researcher at Cambridge University, highlighted that while the trial showed benefits, side effects and long-term safety remain important considerations.
Adverse effects were more common among orforglipron users. Approximately 9-10% of participants stopped the treatment due to gastrointestinal issues, compared with about 5% of those on semaglutide. Spreckley noted that these effects could affect real-world tolerability outside the trial environment and called for further research on long-term outcomes, including cardiovascular health and sustained effectiveness.
Orforglipron is designed as a daily pill that does not require food or water restrictions, offering a more convenient alternative to injectable treatments such as Ozempic, Wegovy, and Mounjaro. Eli Lilly, which also markets Zepbound and Mounjaro, is positioning orforglipron as a competitor to Novo Nordisk, the current provider of the only approved oral GLP-1 pill.
The pill is under review by the US Food and Drug Administration. If approved, Eli Lilly said US patients with obesity could access the drug starting at $149 (€125.92) for the lowest dose, with higher doses priced up to $399 (€337) if insurance does not cover the cost.
As pharmaceutical companies race to make weight-loss treatments more accessible, orforglipron’s strong results highlight the potential of oral GLP-1 therapies to reshape the market, even as questions about side effects and long-term safety remain.
Health
Genetic Differences May Shape Effectiveness of Popular Weight-Loss Drugs, Study Finds
Health
Seven-Day Meditation Retreat Linked to Measurable Changes in Brain and Body, Study Finds
Health
Uzbekistan to Launch Nationwide State Medical Insurance System in 2026
Uzbekistan will begin introducing a nationwide state medical insurance system from 2026, part of a broader overhaul of the country’s healthcare financing and service delivery. The reform will introduce digital referrals, a national health insurance fund, and a guaranteed package of essential medical services funded through the state budget. Officials say the changes aim to improve efficiency, expand access, and reduce informal payments.
“State health insurance is a social protection system designed to guarantee access to quality healthcare services,” said Zokhid Ermatov, executive director of the State Health Insurance Fund.
Discussions about state medical insurance in Uzbekistan began in 2017, but implementing such a system required years of preparation. The State Health Insurance Fund was formally established in December 2020, and pilot programmes launched in the Syrdarya region in 2021 tested new financing mechanisms, regulatory frameworks, and digital health systems. In November 2025, the Cabinet of Ministers approved regulations governing how medical care funded through the state budget will be provided in public and private medical institutions, with the rules set to come into force on January 1, 2026.
At the centre of the new model is stronger primary healthcare. Patients will first visit their assigned family clinic, where doctors provide consultations, prescribe tests, and determine whether specialist care is needed. If necessary, patients will receive an electronic referral to hospitals or specialists. Emergency and urgent care will remain available without referrals.
The reform introduces a patient-centred financing model, where healthcare providers are paid by the State Health Insurance Fund based on services delivered. Primary healthcare will be funded through capitation payments, while hospital treatment will follow case-based payments, a structure designed to improve efficiency and treatment outcomes.
A fully digital referral system will allow patients to choose hospitals from a list of institutions contracted with the State Health Insurance Fund using a government portal or mobile app. Referrals will remain valid for 60 days, and waiting lists and hospitalisations will be managed through a unified electronic health information system.
The insurance system guarantees essential healthcare services, including family doctor consultations, diagnostic tests, outpatient treatment, preventive screening, some medicines, hospital care, and certain rehabilitation services. Patients will not be charged additional fees for services included in the approved package.
Funding for the program will come primarily from the state budget, ensuring citizens do not pay direct insurance contributions. Priority access will be given to socially vulnerable groups, including children with disabilities, orphans, pensioners, pregnant women, unemployed citizens, and low-income families. The State Health Insurance Fund will allocate resources across regions to strengthen medical services and reduce inequalities.
International organisations have praised Uzbekistan’s approach, noting that general tax financing and universal coverage can improve financial protection and ensure predictable healthcare funding. Jessika Yin, Health Policy Adviser at the World Health Organization in Uzbekistan, said the reforms align with global trends toward universal health coverage.
If implemented successfully, Uzbekistan’s state medical insurance system could represent a major step toward universal healthcare, ensuring that people receive care without facing financial hardship.
-
Entertainment2 years agoMeta Acquires Tilda Swinton VR Doc ‘Impulse: Playing With Reality’
-
Business2 years agoSaudi Arabia’s Model for Sustainable Aviation Practices
-
Business2 years agoRecent Developments in Small Business Taxes
-
Home Improvement1 year agoEffective Drain Cleaning: A Key to a Healthy Plumbing System
-
Politics2 years agoWho was Ebrahim Raisi and his status in Iranian Politics?
-
Sports2 years agoChina’s Historic Olympic Victory Sparks National Pride Amid Controversy
-
Business2 years agoCarrectly: Revolutionizing Car Care in Chicago
-
Sports2 years agoKeely Hodgkinson Wins Britain’s First Athletics Gold at Paris Olympics in 800m
